Home  |  Contact

UniProtKB/Swiss-Prot Q9UL46: Variant p.His89Pro

Proteasome activator complex subunit 2
Gene: PSME2
Variant information

Variant position:  89
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Histidine (H) to Proline (P) at position 89 (H89P, p.His89Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (H) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  89
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  239
The length of the canonical sequence.

Location on the sequence:   PDPPPKDDEMETDKQEKKEV  H KCGFLPGNEKVLSLLALVKP
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PDPPPKDDEMETDKQEKKEVHKCGFLPGNEKVLSLLALVKP

Mouse                         PDPPPKDDEMETDKQEKKEVPKCGYLPGNEKLLALLALVKP

Rat                           PDPPPKDDEMETE-QEKKEVPKCGFLPGNEKLLALLALVKP

Pig                           PDPPPKDDEMETDKQEKKEVPKCGFLPGNEKILALLGLVKP

Bovine                        PDPPPKDDEMETDKQEKKEVPKCGFLPGNEKVLALLALVKP

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 239 Proteasome activator complex subunit 2


Literature citations

Organization of the genes encoding the human proteasome activators PA28alpha and beta.
McCusker D.; Wilson M.; Trowsdale J.;
Immunogenetics 49:438-445(1999)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT PRO-89;

Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome.
Ahn J.Y.; Tanahashi N.; Akiyama K.; Hisamatsu H.; Noda C.; Tanaka K.; Chung C.H.; Shibmara N.; Willy P.J.; Mott J.D.; Slaughter C.A.; DeMartino G.N.;
FEBS Lett. 366:37-42(1995)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT PRO-89;

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT PRO-89;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.